(Q39343357)

11 September 2017

title

The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis (English)

1 reference

11 September 2017

1 reference

Li Li Zhou

1

1 reference

11 September 2017

Wei Cao

2

1 reference

11 September 2017

Chao Xie

3

1 reference

11 September 2017

Jianwei Tian

4

1 reference

11 September 2017

Zhanmei Zhou

5

1 reference

11 September 2017

Qiugen Zhou

6

1 reference

11 September 2017

Ping Zhu

7

1 reference

11 September 2017

Aiqing Li

8

1 reference

11 September 2017

Youhua Liu

9

1 reference

11 September 2017

Toshio Miyata

10

1 reference

11 September 2017

Fan Fan Hou

11

1 reference

11 September 2017

Jing Nie

12

1 reference

11 September 2017

language of work or name

English

0 references

publication date

23 May 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

82

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

759-770

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2012.184

11 September 2017

exact match

0 references

cites work

Chronic renal diseases as a public health problem: epidemiology, social, and economic implications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Podocyte loss and progressive glomerular injury in type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Glomerular cell number in normal subjects and in type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Podocytopenia and disease severity in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Prediction of early progression in recently diagnosed IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Advanced oxidation protein products as a novel marker of oxidative stress in uremia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Protein oxidation in obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury: a proteomic analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

RAGE axis: Animal models and novel insights into the vascular complications of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Advanced oxidation protein products: a causative link between oxidative stress and podocyte depletion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

RAGE and modulation of ischemic injury in the diabetic myocardium

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

New advances in renal amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Maillard reactions by alpha-oxoaldehydes: detection of glyoxal-modified proteins

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Detection of advanced oxidation protein products in patients with chronic kidney disease by a novel monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Preventive effect of Notch signaling inhibition by a gamma-secretase inhibitor on peritoneal dialysis fluid-induced peritoneal fibrosis in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.184

7 January 2021

Identifiers

DOI

10.1038/KI.2012.184

1 reference

11 September 2017

1 reference